1067244-40-9

Upstream product

• 55094-97-8 (S)-dimethyl 2-hydroxypentanedioate 
• 58479-61-1 tert-butylchlorodiphenylsilane 

Downstream Products

• 1067244-41-0 (2S)-2-(tert-butyldiphenylsilyloxy)pentane-1,5-diol 
• 1395821-23-4 C₃₁H₅₁NO₃Si₂ 
• 1395819-17-6 C₂₂H₃₁NO₂Si 
• 1395819-61-0 C₂₃H₃₃NO₂Si 
• 1395819-03-0 (3S)-3-tert-butyldiphenylsilyloxy-3,4,5,6-tetrahydropyridine N-oxide 
• 1395819-14-3 (5S)-5-tert-butyldiphenylsilyloxy-3,4,5,6-tetrahydropyridine N-oxide 
• 1395819-65-4 C₂₄H₃₅NO₂Si 
• 1395819-69-8 C₂₈H₃₅NO₂Si 
• 1395819-74-5 C₂₄H₃₃NO₂Si 
• 1395819-79-0 C₂₃H₃₁NO₂Si 
• 1395819-89-2 C₂₉H₃₇NO₄Si 
• 1395819-94-9 C₂₆H₃₂N₂O₂Si 
• 1395819-99-4 C₂₅H₃₇NO₂Si 
• 1395820-03-7 C₂₅H₃₇NO₂Si 

Relevant academic research and scientific papers

A divergent approach to 3-piperidinols: A concise syntheses of (+)-swainsonine and access to the 1-substituted quinolizidine skeleton

Nucleophilic addition of Grignard reagents and organolithium species to a 3-silyloxy-3,4,5,6-tetrahydropyridine Noxide provides trans-2,3-disubstituted N-hydroxypiperidines exclusively. The application of this methodology to the preparation of a diversity of useful trans-2-substituted-3-hydroxypiperidines, a concise synthesis of (+)-swainsonine, and an enantiopure 1- substituted quinolizidine of utility in target-directed synthesis is reported.

HIV PROTEASE INHIBITORS AND METHODS FOR USING

Compounds that inhibit proteolytic enzymes of Human Immunodeficiency Virus (HIV) are described. Preparation of the inhibitors, pharmaceutical compositions containing them, and uses of the compounds or compositions for the treatment of HIV infections are also described.

Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: Design, synthesis, biological evaluation, and protein-ligand X-ray studies

We report the design, synthesis, and biological evaluation of a series of novel HIV-1 protease inhibitors. The inhibitors incorporate stereochemically defined flexible cyclic ethers/polyethers as high affinity P2-ligands. Inhibitors containing small ring 1,3-dioxacycloalkanes have shown potent enzyme inhibitory and antiviral activity. Inhibitors 3d and 3h are the most active inhibitors. Inhibitor 3d maintains excellent potency against a variety of multi-PI-resistant clinical strains. Our structure-activity studies indicate that the ring size, stereochemistry, and position of oxygens are important for the observed activity. Optically active synthesis of 1,3-dioxepan-5-ol along with the syntheses of various cyclic ether and polyether ligands have been described. A protein-ligand X-ray crystal structure of 3d-bound HIV-1 protease was determined. The structure revealed that the P2-ligand makes extensive interactions including hydrogen bonding with the protease backbone in the S2-site. In addition, the P2-ligand in 3d forms a unique water-mediated interaction with the NH of Gly-48.